文献速递血管炎

巨细胞动脉炎患者托珠单抗减量 vs 突然停药:来自三级中心的真实世界经验

Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center.
PubMed 文献 · Semin Arthritis Rheum · 2024-07-04

这项单中心回顾性队列研究纳入2012至2022年接受托珠单抗治疗的155例巨细胞动脉炎患者,其中104例停药。减量组复发无生存期长于突然停药组,突然停药组至复发时间显著更短(p=0.02),15%患者因不良事件停用托珠单抗。

要点

  • 减量组至复发时间显著长于突然停药组(p=0.02)。
  • 每2周给药者6/38(16%)复发,每3周给药者2/19(11%)复发。
  • 突然停药组59例中27例(46%)随访期间复发。

核心结论

  • 本研究首次表明托珠单抗减量较突然停药诱导更长的复发无生存期,提示巨细胞动脉炎患者减量可能优于停药。

研究设计与样本

  • 2012至2022年单中心回顾性队列研究,数据来自电子病历,纳入155例接受托珠单抗治疗的巨细胞动脉炎患者。
  • 采用Kaplan-Meier图报告复发无生存期,用Wilcoxon-Brewlos-Gehan检验比较减量与突然停药。

主要发现

  • 104例停用托珠单抗的患者中,42例(40%)在停药后第一年内复发。
  • 57例接受减量,其中每2周给药时6/38(16%)复发,每3周给药时2/19(11%)复发。
  • 59例突然停药,随访期间27例(46%)复发。
  • 突然停药组至复发时间显著短于所有减量患者(p=0.02),也显著短于从每周治疗减至每2周的患者(p<0.01)。
  • 15%的患者因不良事件停用托珠单抗。

临床怎么用

  • 作者认为,巨细胞动脉炎患者减量可能优于停药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Following the approval of tocilizumab (TCZ) for giant cell arteritis (GCA), recent studies have shown a high relapse frequency after abrupt discontinuation of TCZ. However, a thorough exploration of TCZ tapering compared to abrupt discontinuation has never been undertaken. Likewise, adverse events have only been scarcely investigated in routine care. This study aimed to compare the incidence of relapses in GCA patients undergoing TCZ tapering compared to abrupt discontinuation. METHODS: We performed a single-center retrospective cohort study from 2012 to 2022. Data from GCA patients treated with TCZ was obtained from the Electronic Patients Record. Relapse-free survival is reported in Kaplan-Meier plots and tapering versus abrupt discontinuation were compared using a Wilcoxon-Brewlos-Gehan test. RESULTS: We included 155 patients receiving TCZ treatment for GCA, of which 104 discontinued TCZ. Among the 104 patients discontinuing TCZ, 42 (40 %) experienced a relapse within the first year. A total of 57 patients underwent taper with 6/38 (16 %) and 2/19 (11 %) relapsing while receiving TCZ every second or third week, respectively. In comparison, 59 patients underwent abrupt discontinuation with 27 (46 %) relapsing during follow-up. The patients undergoing abrupt TCZ discontinuation demonstrated a significantly shorter time to relapse compared to all tapered patients (p = 0.02) as well as patients tapered from weekly TCZ treatment to every second week (p < 0.01). Furthermore, 15 % of patients discontinued TCZ due to adverse events. CONCLUSION: This is the first study indicating that TCZ taper induced longer relapse-free survival than abrupt discontinuation, implying that taper may be favored over discontinuation in patients with GCA.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Nielsen MK, Nielsen AW, Donskov AO, et al. Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center. Semin Arthritis Rheum. 2024. PMID: 38981187. doi:10.1016/j.semarthrit.2024.152508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。